Biography
Ken Redekop, Ph.D. is an associate professor at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.
Erasmus School of Health Policy & Management
Associate professor | Health Technology Assessment (HTA)
- redekop@eshpm.eur.nl
- Room
- J8-29
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- L. A. Visser, I. den Uijl, W. K. Redekop, M. Sunamura, M. Lenzen, E. Boersma, R. W.M. Brouwers, H. M.C. Kemps, H. J.G. van den Berg-Emons & N. ter Hoeve (2023) - Cost-Effectiveness of a Cardiac Rehabilitation Program Specifically Designed for Patients With Obesity Within the OPTICARE XL Randomized Controlled Trial - Archives of Physical Medicine and Rehabilitation, 104 (6), 855-862 - doi: 10.1016/j.apmr.2023.02.005 - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment - Frontiers in Health Services, 3 - doi: 10.3389/frhs.2023.1034256
- Remziye Zaim, W. Ken Redekop & Carin A. Uyl-de Groot (2023) - Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer - Frontiers in Oncology, 13, 1027659 - doi: 10.3389/fonc.2023.1027659 - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer - Journal of Cancer Policy, 35 - doi: 10.1016/j.jcpo.2022.100382
- Gimon de Graaf, Ivy Timmermans, Mathias Meine, Marco Alings, Susanne S Pedersen, Philippe Mabo, Edgar Zitron, Ken Redekop & Henneke Versteeg (2022) - Economic evaluation of remote monitoring of patients with an implantable cardiac defibrillator (REMOTE-CIED study) - Journal of Telemedicine and Telecare, 1-13 - doi: 10.1177/1357633X221129176 - [link]
- Remziye Zaim, Ken Redekop & C.A. (Carin) Uyl - de Groot (2022) - Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer - Translational Oncology, 20 - doi: 10.1016/j.tranon.2022.101418 - [link]
- Sara Landerdahl Stridsberg, Matt X. Richardson, Ken Redekop, Maria Ehn & Sarah Wamala Andersson (2022) - Gray Literature in Evaluating Effectiveness in Digital Health and Health and Welfare Technology: A Source Worth Considering - Journal of Medical Internet Research, 24 (3), e29307 - doi: 10.2196/29307 - [link]
- Feline F.J.A.Ter Bruggen, W. Ken Redekop, Dirk L. Stronks & Frank J.P.M. Huygen (2021) - Long-term effects of dexmedetomidine versus propofol during the implantation of a neurostimulator—a post-trial follow-up analysis - Journal of Pain Research, 14, 3631-3636 - doi: 10.2147/JPR.S323961 - [link]
- L. A. Visser, S. P.I. Huls, C. A. Uyl-de Groot, E. W. de Bekker-Grob & W. K. Redekop (2021) - An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries - Journal of the Neurological Sciences, 428 - doi: 10.1016/j.jns.2021.117587 - [link]
- Laurenske A. Visser, Marc Folcher, Claudia Delgado Simao, Biotza Gutierrez Arechederra, Encarna Escudero, Carin A. Uyl-de Groot & William Ken Redekop (2021) - The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis - PharmacoEconomics, 40 (1), 91-108 - doi: 10.1007/s40273-021-01081-y - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2022
- Course Code
- GW4560M
Master Thesis HE
- Year Level
- master, master
- Year
- 2022
- Course Code
- GW4592M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2022
- Course Code
- GW4555M
Integration project
- Level
- bachelor 2
- Year Level
- bachelor 2
- Year
- 2022
- Course Code
- GW205I
Academic Development & Skills
- Level
- bachelor 2
- Year Level
- bachelor 2
- Year
- 2022
- Course Code
- GW205AVV
Module Knowledge
- Level
- bachelor 2
- Year Level
- bachelor 2
- Year
- 2022
- Course Code
- GW205K
f